Trials / Withdrawn
WithdrawnNCT01184287
A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer
A Phase II Trial of Addition of Ranpirnase(ONCONASE®) to Permetrexed Plus Carboplatin in Patientes With Non-Squamous Non-Small Cell Lung Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Tamir Biotechnology, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the trial is to determine the rate of improvement in objective tumor response, following the addition of ranpirnase to ongoing pemetrexed-carboplatin chemotherapy, for patients with SD or PR following 2 cycles of doublet chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranpirnase | Cycles 3 and until patient progression, on days 1,8 and 15 in a 21 day cycle |
Timeline
- First posted
- 2010-08-18
- Last updated
- 2015-09-02
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01184287. Inclusion in this directory is not an endorsement.